Leading Innovators in Gene Therapy Market: 5 Biggest Stocks Companies in 2023

In recent years, there has been a notable surge in the prevalence of rare diseases worldwide, leading to a heightened need for advancements in cell and gene therapy. Particularly, ex-vivo gene therapy has gained widespread recognition as an effective approach for addressing neurological conditions. As a result, the gene therapy market is projected to experience substantial growth until 2032 due to the escalating demand for these innovative treatments.

The growth of the global gene therapy industryt is impeded by the expensive nature of these medical procedures, requiring substantial investments from providers and patients alike.

The utilization of precision equipment in gene modifications significantly contributes to the high costs associated with cell and gene therapy, thereby restricting their widespread adoption worldwide. Consequently, viral vector gene therapies are anticipated to exhibit the slowest growth rate due to their higher costs and lower adoption rates.

Gene Therapy Market Growth Outlook (2022-2032)

The global gene therapy market size was valued at US$ 1.55 Billion in 2021. The market is projected to grow from US$ 1.85 Billion in 2022 to US$ 10.1 Billion by 2032, exhibiting a CAGR of 18.5% during the forecast period. Read more @ https://lnkd.in/dSiM-hzr

Breaking Developments in Gene Therapy: Latest News and Updates of Top Key Players

Adverum Biotechnologies Unveils Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Promising Data on their Ocular Gene Therapy Platform

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company dedicated to advancing gene therapy as the new standard of care for prevalent ocular diseases, has unveiled new nonclinical data at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California. The data highlights an intravitreal (IVT) gene therapy for treating geographic atrophy (GA) caused by dry age-related macular degeneration (dry AMD) through the expression of complement factor I (CFI). Additionally, Adverum presented research pipeline data that showcases the effectiveness of its proprietary adeno-associated virus (AAV) vector platform in ocular gene therapy. This includes presentations on optogenetics and Chemistry, Manufacturing, and Controls (CMC) strategies for AAV-mediated gene therapies targeting prevalent diseases.

Dr. Brigit Riley, Chief Scientific Officer of Adverum Biotechnologies, expressed enthusiasm for the company's platform, stating, "Our ability to deliver both CFI and an engineered melanopsin using our proprietary capsids through IVT administration demonstrates the strength of our platform at Adverum. Patients with GA, similar to those with wet AMD, currently face frequent injections or faster lesion growth and vision decline. We are in the early stages of developing a therapeutic for GA and are excited about the potential to revolutionize treatment for dry AMD patients worldwide with a single, in-office IVT injection that creates CFI biofactories in the retina."

eGenesis Trudges Towards the Clinic

eGenesis, a biotechnology company founded by George Church and Luhan Yang, is dedicated to developing human-compatible organs and cells for the treatment of organ failure and other debilitating diseases. Their focus lies in addressing the global shortage of transplant organs and revolutionizing the treatment of organ failure. With a particular emphasis on kidney and islet cell transplantation, eGenesis utilizes gene editing technologies such as CRISPR to overcome the challenges associated with xenotransplantation.

To address the risks associated with xenotransplantation, eGenesis tackles two critical issues. Firstly, they deactivate all endogenous retrovirus sequences within the porcine genome, eliminating the potential for viral transmission from pig to human. Additionally, they employ biosecure, pathogen-free animal production processes to mitigate the risk of transmitting other viruses. In a significant breakthrough, eGenesis successfully demonstrated the inactivation of Porcine Endogenous Retrovirus (PERV) and produced the first PERV-free pigs, a significant milestone for xenotransplantation. Secondly, the company utilizes multiplex gene editing to comprehensively address the various mechanisms of immune-mediated rejection that occur after organ transplantation.

Through their pioneering research and development efforts, eGenesis aims to revolutionize the field of transplantation and provide a solution to the pressing needs of patients suffering from organ failure and other debilitating conditions.

Cell and gene therapy: The next milestone in fighting diseases

Bayer: The field of cell and gene therapy is on the verge of ground breaking advancements that have the potential to revolutionize healthcare. By focusing on our genetic and cellular makeup, this emerging branch of medicine offers a new paradigm that holds promise for curing even the most challenging diseases. Cell and gene therapy delve into the molecular level of illnesses, aiming to replace damaged or malfunctioning molecules within our bodies.

Together, cell and gene therapy have the capacity to transform our approach to combating diseases. Notably, significant progress has been made in oncology, where therapies like CAR-T (Chimeric Antigen Receptor T-cell) have demonstrated remarkable potential. CAR-T therapies involve extracting and reprogramming immune cells known as T-cells to enhance their ability to detect and eliminate cancer cells, leading to encouraging results.

The future of cell and gene therapy is highly exciting, as it could pave the way for more targeted and personalized treatments. This innovative approach also holds the potential to overcome diseases that were once considered incurable. As scientists continue to explore this field, the possibilities for advancements in healthcare and the potential for improved patient outcomes are vast.

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs

Taysha Gene Therapies, a promising player in AAV (Adeno-Associated Virus) gene therapies, has entered into a new collaboration aimed at advancing the development of two of Taysha's innovative product candidates. These candidates target rare monogenic central nervous system diseases that currently lack effective medical solutions.

As part of the collaboration, Astellas, a leading pharmaceutical company, will invest a total of $50 million to acquire a 15% stake in Taysha. In addition to the investment, Astellas will gain an exclusive option to secure a license for TSHA-102, intended for the treatment of Rett syndrome, and TSHA-120, targeting giant axonal neuropathy (GAN).

The agreement also grants Astellas certain rights related to any potential change of control of Taysha, ensuring their involvement in important decision-making processes. Moreover, Astellas will secure one Board observer seat on the Taysha Board of Directors, further strengthening their collaboration and strategic partnership.

Gene Therapy Stocks: 5 Biggest Companies in 2023

Novartis AG (NYSE: NVS): Novartis has been a key player in gene therapy, particularly with its breakthrough CAR-T therapy, Kymriah, for certain types of cancer. They continue to invest in gene therapy research and development.

bluebird bio, Inc. (NASDAQ: BLUE): bluebird bio is known for their gene therapies targeting rare genetic diseases and genetic-based blood disorders. They have developed therapies like Zynteglo and LentiGlobin.

Spark Therapeutics, Inc. (a Roche company): Spark Therapeutics gained recognition for their gene therapy Luxturna, approved for the treatment of inherited retinal diseases. They have a strong focus on developing innovative gene therapies for various genetic disorders.

uniQure N.V. (NASDAQ: QURE): uniQure specializes in gene therapies for rare genetic diseases, particularly focusing on treatments for hemophilia. They have investigational therapies like AMT-061 and AMT-130 in their pipeline.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT): Sarepta is dedicated to developing gene therapies for genetic-based neuromuscular diseases. They have therapies like Exondys 51 for Duchenne muscular dystrophy and are actively engaged in advancing their gene therapy pipeline.

It's worth noting that the gene therapy landscape is dynamic, with new companies emerging and established players advancing their research and development efforts. Market conditions and company performance can also influence rankings. It's advisable to consult updated financial reports and market analysis for the most accurate and current information on the biggest gene therapy companies.